TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03545282

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Amigas Latinas Motivando el Alma (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions.
Study: NCT00459056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril + HCTZ
Description: Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
Study: NCT03233880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 1gm
Description: Azithromicin 1 gm oral single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo
Study: NCT03216928

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Study: NCT05513118

Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling
Description: Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit.
Study: NCT01802853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6811135
Description: Single subcutaneous dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO6811135
Description: Single intravenous dose
Study: NCT04570215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gotcha! Therapy application
Description: Gotcha! will provide an app-based therapy for people with dementia who have difficulty naming people they know well.~The therapy element works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. This DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gotcha! Therapy application
Description: Gotcha! will provide an app-based therapy for people with dementia who have difficulty naming people they know well.~The therapy element works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. This DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gotcha Therapy application: Maintenance
Description: Gotcha! Maintenance therapy is identical to Gotcha! but takes place over a longer period of time in an attenuated form.
Study: NCT04082858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
Study: NCT04278391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1421
Description: 1 tablet administered in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC201903
Description: 1 tablet administered in fasting condition
Study: NCT01644058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading
Study: NCT02350621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Study: NCT03545282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amigas Latinas Motivando el Alma (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions.
Study: NCT02350621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimal invasive Posterior Cervical Foraminotomy
Study: NCT01963728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Isophane
Description: daily dosing based on fasting morning glucose levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: daily dose based on fasting morning glucose levels
Study: NCT00961168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume Control Ventilation
Description: Mechanical ventilation at a constant tidal volume of 6 mL/kg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation
Description: Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
Study: NCT01616381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: PDE-5 Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for sildenafil 40mg x 3 daily
Study: NCT01808794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucograft
Description: Mucograft Collagen Matrix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamatrix
Description: Dynamatrix
Study: NCT04138979

Intervention type: DRUG
Intervention: cyclophosphamide
Description: First use of chemotherapy after breast cancer
Study: NCT02386683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lung-protective ventilation
Description: mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
Study: NCT02890615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression self-care
Description: Toolkit and coaching
Study: NCT02535780

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: TMS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: TMS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS
Study: NCT03320525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-ChOS
Description: T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
Study: NCT01247805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Single oral dose of 1 x 20 mg IR oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
Study: NCT00248560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
Study: NCT01762579

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat flour
Description: wheat flour is administered three times per day for 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: wheat flour
Description: wheat flour is administered three times per day for 15 days
Study: NCT02628925

Intervention type: DEVICE
Intervention: Nu-DESC DK
Description: Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
Study: NCT02726399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80mg/m2 administered as an IV infusion every 21 days
Study: NCT00635713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 125mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: ARIMIDEX
Study: NCT01762579

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Xylose
Description: Xylose will be administered three times per day for 15 days
Study: NCT00635713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: ARIMIDEX
Study: NCT00635713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250mg
Study: NCT02131883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Cognitive Behavioral Therapy
Description: psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-List with treatment as usual
Description: Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
Study: NCT02139319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01339169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: 50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
Study: NCT01659905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Chewable Tablet
Study: NCT01762579

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylose
Description: Xylose will be administered three times per day for 15 days
Study: NCT03568838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
Study: NCT01238120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 200 mg BID and 8 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 200 mg BID and 8 hours apart

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise
Description: A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise
Description: A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg BID and 8 hours apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 200mg BID and 8 hours apart
Study: NCT04453111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placenta-derived MMSCs
Description: Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived MMSCs
Description: Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalgan 20 mg in 2 ML Prefilled Syringe
Description: Hyaluronic Acid 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyalgan 20 mg in 2 ML Prefilled Syringe
Description: Hyaluronic Acid 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyalgan 20 mg in 2 ML Prefilled Syringe
Description: Hyaluronic Acid 20 mg
Study: NCT03934762

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Aloe Vera
Description: Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
Study: NCT01659905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 5 mg Chewable Tablet
Study: NCT01901783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With primary closure
Description: A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without primary closure
Description: A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
Study: NCT03429634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon-Stent Kissing technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Balloon-Stent Kissing technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jailed Wire technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Jailed Wire technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
Study: NCT04325256

Intervention type: PROCEDURE
Intervention: Manipal ultrasound scoring system
Description: length of the cervix from the internal to external os, presence or absence of funneling and if present width and length of funneling at internal os were measured. Distance between presenting part to external os will be measured and position of the cervix i.e. whether curved or straight will also noted.

Intervention type: PROCEDURE
Intervention: Levine scoring system
Description: maternal height, parity, body-mass index (BMI) at delivery and the results of modified Bishop's score in calculation of probability of CS
Study: NCT02465320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COL-1077
Description: single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of bioadhesive gel administered by intravaginal insertion
Study: NCT01286922

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral: exercise
Description: Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: exercise
Description: Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group.
Study: NCT04605861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
Study: NCT01838720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero ischemia laparoscopic RFA assisted TE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemia
Description: conventional laparoscopic partial nephrectomy
Study: NCT02496546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731 cream
Description: Applied for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731 cream vehicle
Description: Applied for 3 weeks
Study: NCT01354860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment plus usual care
Description: Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Usual care alone group
Description: Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline.
Study: NCT01601145

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: consumption of lozenges
Description: Each subject two lozenges a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: consumption of lozenges
Description: Each subject two lozenges a day for 6 weeks
Study: NCT03414593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine
Description: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine
Description: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml